Bionomics Ltd is an Australia-based clinical-stage biopharmaceutical company. Co. is focused on development of novel drug candidates focused on the treatment of serious central nervous system disorders. It is developing novel allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. It is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the ?7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). We show 2 historical shares outstanding datapoints in our NEUP shares outstanding history coverage, used to compute NEUP market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing NEUP market cap history over the course of time is important for investors
interested in comparing NEUP's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of NEUP versus a peer is one thing; comparing
NEUP market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like NEUP can fluctuate over the course of history.
With this page we aim to empower investors researching NEUP by allowing them to research the NEUP market cap history. |
Free NEUP Email Alerts:
Video: The Importance of Market Cap
